Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Drug Discovery & Development

CytRx reports overall survival results from phase IIb trial of aldoxorubicin CytRx, a biopharmaceutical research and development company specializing in oncology, announced encouraging overall survival (OS) results, the secondary endpoint, from its completed multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS).
Drug Research > Drug Discovery & Development > News
Curis, Aurigene partner to develop precision oncology targets Curis and Aurigene Discovery Technologies have entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets.
Drug Research > Drug Discovery & Development > News Tobira begins dosing in Phase I trial of cenicriviroc and pioglitazone By PBR Staff Writer
US-based biopharmaceutical firm Tobira Therapeutics has started dosing in a Phase I trial to evaluate the pharmacokinetics and safety in healthy patients of cenicriviroc (CVC) and the diabetes medication pioglitazone, both when administered alone and in combination.
Drug Research > Drug Discovery & Development > News
See more Drug Discovery & Development news

Latest Drug Discovery & Development News and Insight

View all Drug Discovery & Development news or find news targeted to your interests
Curis, Aurigene partner to develop precision oncology targets
Curis and Aurigene Discovery Technologies have entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets.
Drug Research > Drug Discovery & Development > News
Tobira begins dosing in Phase I trial of cenicriviroc and pioglitazone
By PBR Staff Writer
US-based biopharmaceutical firm Tobira Therapeutics has started dosing in a Phase I trial to evaluate the pharmacokinetics and safety in healthy patients of cenicriviroc (CVC) and the diabetes medication pioglitazone, both when administered alone and in combination.
Drug Research > Drug Discovery & Development > News
Enzymotec begins 24-month clinical trial of Vayacog in MCI patients
By PBR Staff Writer
Israel-based Enzymotec has started a clinical trial to evaluate the long term efficacy of Vayacog in patients with Mild Cognitive Impairment (MCI).
Drug Research > Drug Discovery & Development > News
Caris Molecular Intelligence identifies therapeutic options for patients with ASCC
Caris Life Sciences announced the presentation of data from a study in which Caris Molecular Intelligence, the company's panomic, comprehensive tumor profiling service, identified potentially actionable alterations in patients with recurring or metastasized anal squamous cell carcinoma (ASCC), a rare human papilloma virus (HPV)-associated malignancy accounting for 2.4% of digestive system cancers.
Drug Research > Drug Discovery & Development > News
Boehringer, Sanofi partner to produce monoclonal antibodies
By PBR Staff Writer
Germany-based Boehringer Ingelheim has entered into a strategic agreement with French pharmaceutical firm Sanofi to manufacture therapeutic monoclonal antibodies.
Drug Research > Drug Discovery & Development > News
AstraZeneca reports PEGASUS-TIMI 54 trial meets primary endpoint
AstraZeneca announced that the PEGASUS-TIMI 54 study, a large scale outcomes trial involving over 21,000 patients, successfully met its primary efficacy endpoint.
Drug Research > Drug Discovery & Development > News
Merck, Moderna to develop mRNA-based antiviral vaccines and passive immunity therapies
By PBR Staff Writer
Merck and Moderna Therapeutics have agreed to a license and three-year research collaboration deal to discover and develop modified messenger RNA-based (mRNA) vaccines and passive immunity treatments against viral diseases.
Drug Research > Drug Discovery & Development > News
BioMarin reports positive preliminary data from Phase I/II trial of BMN 190
BioMarin Pharmaceutical announced interim results from its Phase I/II pivotal study for BMN 190 or cerliponase alfa, a recombinant human tripeptidyl peptidase 1 (rhTPP1), to treat of patients with late infantile CLN2 disease, a form of Batten disease.
Drug Research > Drug Discovery & Development > News
Proteros, Bayer to develop new cardiovascular drug compounds
By PBR Staff Writer
Proteros biostructures has entered into a drug discovery research collaboration with Bayer Pharma (Bayer) for new compounds to treat cardiovascular diseases.
Drug Research > Drug Discovery & Development > News
CytRx reports positive interim Phase II aldoxorubicin results
CytRx, a biopharmaceutical research and development company specializing in oncology, announced positive interim results from its ongoing Phase II clinical trial evaluating the safety and efficacy of aldoxorubicin for the treatment of Kaposi's Sarcoma (KS) in HIV-infected patients.
Drug Research > Drug Discovery & Development > News
View all Drug Discovery & Development news or find news targeted to your interests

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250